… azacitidine and decitabine … for patients and physicians. Therefore, the objective of this study
was to compare the efficacy and safety of azacitidine and decitabine in elderly AML patients …

… Little is known about the comparative effectiveness of azacitidine versus decitabine, … of
azacitidine compared to decitabine in the management of older MDS patients in the USA. …

… Older patients with acute myeloid … with decitabine or azacitidine from a large, multicenter,
phase 1b dose-escalation and expansion study. Patients (N = 145) were at least 65 years old …

… Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and
… Treatment with hypomethylating agents such as azacitidine and decitabine is common, but …

… decitabine and azacitidine in patients with MDS. Eleven trials with a total of 1392 patients with
MDS (decitabine, n = 768; azacitidine… , especially in elderly patients or those with high risk. …

… the safety and preliminary efficacy of VEN in combination with decitabine (DEC) or azacitidine
(AZA). Eligible patients included those ≥65 years of age with previously untreated AML (…

… Low-dose decitabine versus best supportive care in elderly patients with intermediate- or
high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results …

… Citation21 Aside from clinical trials, the current National Comprehensive Cancer Care
guidelines suggest clofarabine, 5-azacitidine, and decitabine as alterative options for this …

… We compared the efficacy of azacitidine (AZA) and decitabine (DEC) in elderly patients
with untreated AML, diagnosed according to WHO criteria. In the two groups, we evaluated …

… elderly study participants. If the inferior survival in elderly patients who received decitabine
is … infection, we would suggest azacitidine as the preferred treatment option in these patients. …